Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?

Amgen looks stronger on fundamentals, with FY2025 revenue of nearly $36.8 billion, net income of $7.7 billion, and free cash flow of about $8.1 billion, while NovoCure posted $655.4 million of revenue but a $136.2 million net loss and negative free cash flow of $75.7 million. The article favors Amgen for 2026 due to its scale, dividend, and ability to fund growth, despite regulatory and litigation risks. NovoCure’s FDA-approved Optune Pax is a positive catalyst, but funding needs and slower growth keep the risk profile elevated.

Analysis

AMGN is the cleaner compounding vehicle here because the market is still pricing it like a mature pharma utility despite meaningful optionality from capital allocation. The second-order setup is that its free cash flow can be redirected into bolt-on M&A or aggressive buybacks just as smaller biotech funding remains tighter, which should keep relative multiples supported even if top-line growth stays pedestrian. NVCR, by contrast, is still in the capital-dependency phase: even if adoption improves, every incremental indication increase lengthens the cash burn runway before the equity can de-rate on fundamentals rather than hope.

The competitive nuance is that NVCR’s model is more vulnerable than it looks because reimbursement friction is a hidden churn driver. If payer coverage delays or claim denials rise, the company effectively self-funds customer acquisition and retention, which compresses unit economics well before headline revenue slows. That creates a much higher sensitivity to quarter-to-quarter execution than the market appears to be discounting, especially versus a diversified incumbent that can absorb one-off legal/regulatory noise.

The contrarian view on AMGN is that the debt load and distributor concentration matter less than the market implies as long as cash conversion stays intact; leverage is only a problem if operating cash flow rolls over, and there is no evidence of that yet. For NVCR, the consensus may be underestimating how long equity holders can be diluted by the financing gap if the company does not reach cash break-even on schedule. This is a years-long story, not a days-weeks catalyst trade, unless a new reimbursement win or label expansion materially changes the funding trajectory.

Net: the setup favors owning AMGN as a defensive cash-yielding compounder and fading NVCR’s valuation rebound risk until the market gets clearer proof of self-funding economics. Any upside surprise in NVCR should be sold into strength unless it comes with visible acceleration in cash burn improvement and payer conversion.

Key Decisions for Investors

• Long AMGN vs short NVCR in a 3-6 month pair trade: express the view that cash flow durability will outperform funding-dependent revenue; target modest alpha with lower factor risk than a directional healthcare basket.
• Buy AMGN on 2-3% pullbacks over the next 1-2 months; risk/reward favors a dividend-supported downside buffer with upside from capital deployment optionality.
• Avoid initiating fresh long NVCR until there is at least one quarter of evidence that reimbursement conversion is improving faster than operating burn; otherwise the dilution overhang can overwhelm any indication-driven pop.
• If NVCR rallies on label expansion news, use call spreads or fade into strength rather than chase common stock; the likely outcome is a multiple move before fundamentals catch up.
• Monitor AMGN leverage and legal/regulatory headlines, but treat them as buy-the-dip events unless free cash flow visibly deteriorates for two consecutive quarters.